title: Effect of calcium acetate/magnesium carbonate in the treatment of hyperphosphataemia in dialysis patients in real clinical practice. One year follow up.
abstract: BACKGROUND
  This observational study was conducted to investigate the use and effectiveness of calcium acetate/magnesium carbonate (CaMg) in the treatment of hyperphosphataemia in dialysis patients in real-world clinical practice.
  
  
  METHODS
  120 adult CKD patients on dialysis who received CaMg alone or in combination with other phosphate binders were followed-up for 3-12 months. Serum phosphorus, calcium, magnesium, parathyroid hormone and albumin concentration was measured at baseline and after 3, 6 and 12 months respectively. In addition, CaMg dosage, use of concurrent phosphate binders, vitamin D and cinacalcet was documented. Patients were evaluated in 2 subgroups &ndash; CaMg alone (n=79) vs. CaMg + concurrent phosphate binder (n=41).
  
  
  RESULTS
  In both subgroups serum phosphorus levels decreased significantly from baseline at 3, 6 and 12 months of CaMg treatment. The percentage achievement of recommended serum phosphorus targets improved after CaMg initiation. At month 6, a total of 78% were within the Kidney Disease Outcomes Quality Initiative (K/DOQI) target range. Total corrected serum calcium increased during CaMg treatment, but mildly exceeded the upper limit of normal in three patients only. Asymptomatic significant increases in magnesium (p&lt;0.001) were observed in the monotherapy group at 3, 6 and 12 months. A total of 80 patients (67%) experienced episodes of mild hypermagnesaemia (&gt;2.6mg/mL, 1.05mmol/L).
  
  
  CONCLUSIONS
  This analysis of current clinical practice shows that &ndash; consistent with findings from a randomised controlled trial &ndash; CaMg treatment leads to marked improvement in serum phosphorus levels, helping patients in trying to achieve K/DOQI and KDIGO (Kidney Disease Improving Global Outcome) targets.
authors.forename: Angel L M
authors.initials: AL
authors.lastname: de Francisco
authors.forename: Lara
authors.initials: L
authors.lastname: Belmar
authors.forename: Celestino
authors.initials: C
authors.lastname: Piñera
authors.forename: María
authors.initials: M
authors.lastname: Kislikova
authors.forename: Miguel
authors.initials: M
authors.lastname: Seras
authors.forename: Mara
authors.initials: M
authors.lastname: Serrano
authors.forename: Zoila
authors.initials: Z
authors.lastname: Albines
authors.forename: Cristina
authors.initials: C
authors.lastname: Sango
authors.forename: Manuel
authors.initials: M
authors.lastname: Arias
mesh_terms: D000085:Acetates / Q000627:therapeutic use*; D017610:Calcium Compounds / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D054559:Hyperphosphatemia / Q000188:drug therapy*; D008274:Magnesium / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D006435:Renal Dialysis; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000085:Acetates; D017610:Calcium Compounds; C005479:magnesium carbonate; D008274:Magnesium; C120662:calcium acetate